Sandbox: sadaf: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 18: Line 18:
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hematoma
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hematoma
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hemarthrosis
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hemarthrosis
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Platelet count
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Plt
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Bleeding time (BT)
! align="center" style="background:#4479BA; color: #FFFFFF;" + |BT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Prothrombin time (PT)
! align="center" style="background:#4479BA; color: #FFFFFF;" + |PT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Activated partial thromboplastin time (aPTT)
! align="center" style="background:#4479BA; color: #FFFFFF;" + |PTT
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Thrombin time (TT)
! align="center" style="background:#4479BA; color: #FFFFFF;" + |TT
|-
|-
! rowspan="14" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelet disorders
! rowspan="14" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelet disorders
Line 37: Line 37:
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
|-
|-
Line 61: Line 61:
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Most important part of treatment is discontinuing of the medication.
| align="center" style="background:#F5F5F5;" | Most important part of treatment is discontinuing of the medication.
|-
|-
Line 78: Line 78:
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | For more information click here: [[Heparin-induced thrombocytopenia]].  
| align="center" style="background:#F5F5F5;" | For more information click here: [[Heparin-induced thrombocytopenia]].  
Line 94: Line 94:
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
|-
|-
Line 110: Line 110:
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
|-
|-
Line 132: Line 132:
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
|-
|-
Line 154: Line 154:
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | ↓
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
|-
|-
Line 180: Line 180:
| align="center" style="background:#F5F5F5;" |±
| align="center" style="background:#F5F5F5;" |±
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Normal or ↑
| align="center" style="background:#F5F5F5;" | Nl or ↑
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
|-
|-
Line 197: Line 197:
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | Rare
| align="center" style="background:#F5F5F5;" | Rare
| align="center" style="background:#F5F5F5;" | Normal or ↓
| align="center" style="background:#F5F5F5;" | Nl or ↓
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="left" style="background:#F5F5F5;" |  
| align="left" style="background:#F5F5F5;" |  
* AR inheritance
* AR inheritance
Line 216: Line 216:
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | Normal or ↓
| align="center" style="background:#F5F5F5;" | Nl or ↓
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="left" style="background:#F5F5F5;" |  
| align="left" style="background:#F5F5F5;" |  
* AR inheritance
* AR inheritance
Line 236: Line 236:
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | Normal or ↓
| align="center" style="background:#F5F5F5;" | Nl or ↓
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="left" style="background:#F5F5F5;" |  
| align="left" style="background:#F5F5F5;" |  
* Anti-WASP antibody can be used to detect presence or absence of WAS protein
* Anti-WASP antibody can be used to detect presence or absence of WAS protein
Line 259: Line 259:
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | Normal or ↓
| align="center" style="background:#F5F5F5;" | Nl or ↓
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="left" style="background:#F5F5F5;" |  
| align="left" style="background:#F5F5F5;" |  
* AD inheritance
* AD inheritance
* Abnormalities of platelet granule formation
* AbNlities of platelet granule formation
|-
|-
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Acquired Disorders of [[Platelet]] Function<span name="harr_c115s002s004s002p001"></span><span name="9100808"></span>
! colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |Acquired Disorders of [[Platelet]] Function<span name="harr_c115s002s004s002p001"></span><span name="9100808"></span>
Line 279: Line 279:
| align="center" style="background:#F5F5F5;" |±
| align="center" style="background:#F5F5F5;" |±
| align="center" style="background:#F5F5F5;" |±
| align="center" style="background:#F5F5F5;" |±
| align="center" style="background:#F5F5F5;" | Normal or ↓
| align="center" style="background:#F5F5F5;" | Nl or ↓
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | −
| align="center" style="background:#F5F5F5;" | −
|-
|-
Line 301: Line 301:
| align="center" style="background:#F5F5F5;" |±
| align="center" style="background:#F5F5F5;" |±
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | Normal
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | See the table below for the details about different types.
| align="center" style="background:#F5F5F5;" | See the table below for the details about different types.
|-
|-
Line 327: Line 327:
| −
| −
| −
| −
|Normal
|Nl
|↑/Normal
|Nl or
|Normal
|Nl
|Normal
|Nl
|Normal
|Nl
|−
|−
|-
|-
Line 348: Line 348:
| −
| −
| −
| −
|Normal
|Nl
|↑/Normal
|Nl or
|Normal
|Nl
|Normal
|Nl
|Normal
|Nl
|−
|−
|-
|-
Line 375: Line 375:
* [[Bleeding]] from the [[umbilical cord]] stump after birth
* [[Bleeding]] from the [[umbilical cord]] stump after birth
* Bleeding after [[dental surgery]] or tooth extraction
* Bleeding after [[dental surgery]] or tooth extraction
* Abnormal bleeding during or after injury, surgery, or childbirth
* AbNl bleeding during or after injury, surgery, or childbirth


* [[Gastrointestinal tract|Gastrointestinal]] [[hemorrhage]]
* [[Gastrointestinal tract|Gastrointestinal]] [[hemorrhage]]
Line 386: Line 386:
| +
| +
|Normal
|Nl
|↑
|↑
|↑
|↑
Line 412: Line 412:
|<nowiki>+</nowiki>
|<nowiki>+</nowiki>
|<nowiki>+</nowiki>
|<nowiki>+</nowiki>
|Normal
|Nl
|Normal
|Nl
|↑
|↑
|↑
|↑
Line 433: Line 433:
| +
| +
| +
| +
|Normal
|Nl
|↑
|↑
|↑
|↑
|↑
|↑
|Normal
|Nl
|The severity of bleeding is only partly related to the degree of factor V deficiency. Some patients with undetectable plasma levels of factor V experience only relatively mild bleeding.
|The severity of bleeding is only partly related to the degree of factor V deficiency. Some patients with undetectable plasma levels of factor V experience only relatively mild bleeding.
|-
|-
Line 454: Line 454:
| +
| +
| +
| +
|Normal
|Nl
|
|
|↑
|↑
|Normal
|Nl
|Normal
|Nl
|Thrombosis occurs in inherited factor VII deficiency  most cases are associated with the administration of factor VII replacement therapy  
|Thrombosis occurs in inherited factor VII deficiency  most cases are associated with the administration of factor VII replacement therapy  
|-
|-
Line 480: Line 480:
| +
| +
| +
| +
|Normal
|Nl
|Normal
|Nl
|↑
|↑
|↑
|↑
|Normal
|Nl
|−
|−
|-
|-
Line 498: Line 498:
|_
|_
|_
|_
|Normal
|Nl
|Normal
|Nl
|Normal
|Nl
|↑
|↑
|Normal
|Nl
|
|
|-
|-
Line 514: Line 514:
|_
|_
|_
|_
|Normal
|Nl
|Normal
|Nl
|Normal
|Nl
|↑
|↑
|Normal
|Nl
|
|
|-
|-
Line 530: Line 530:
|_
|_
|_
|_
|Normal
|Nl
|Normal
|Nl
|Normal
|Nl
|↑
|↑
|Normal
|Nl
|
|
|-
|-
Line 549: Line 549:
|Normal
|Nl
|Normal
|Nl
|Normal/
|Nl or
|Normal
|Nl
|Normal
|Nl
|
|
* Impaired fibrin cross linking or clot dissolution
* Impaired fibrin cross linking or clot dissolution
Line 574: Line 574:
| +
| +
|<nowiki>+</nowiki>
|<nowiki>+</nowiki>
|Normal
|Nl
|Normal
|Nl
|Normal
|Nl
|↑
|↑
|Normal
|Nl
|−
|−
|-
|-
Line 593: Line 593:
| +
| +
|<nowiki>+</nowiki>
|<nowiki>+</nowiki>
|Normal
|Nl
|Normal
|Nl
|Normal
|Nl
|↑
|↑
|Normal
|Nl
|−
|−
|-
|-
Line 610: Line 610:
|Rare
|Rare
|Rare
|Rare
|Normal
|Nl
|Normal
|Nl
|Normal
|Nl
|↑
|↑
|Normal
|Nl
| −
| −
|-
|-
Line 637: Line 637:
|↑
|↑
|↑
|↑
|Normal
|Nl
| −
| −
|-
|-
Line 657: Line 657:
|<nowiki>+</nowiki>
|<nowiki>+</nowiki>
|<nowiki>+</nowiki>
|<nowiki>+</nowiki>
|Normal
|Nl
|↑
|↑
|↑
|↑
|Normal or mildly prolonged
|Nl or mildly prolonged
|Normal
|Nl
| −
| −
|}
|}

Revision as of 15:59, 19 October 2018

Differential Diagnosis

Different causes of the bleeding disorders can be differentiated based on their clinical manifestation and laboratory findings.

These features have discussed in the below table:

Category Sub-category Diseases History Clinical manifestation Laboratory testing Comments
Mucosal bleeding Petechia Ecchymoses Menorrhagia Hematoma Hemarthrosis Plt BT PT PTT TT
Platelet disorders Thrombocytopenia Infection-Induced thrombocytopenia
  • History of prior infection
+ + + + + + Nl Nl Nl
Medications-Induced thrombocytopenia + + + + + + Nl Nl Nl Most important part of treatment is discontinuing of the medication.
Heparin-Induced thrombocytopenia + + + + + + Nl Nl For more information click here: Heparin-induced thrombocytopenia.
Immune Thrombocytopenic Purpura (ITP) + + + + + + Nl Nl Nl
Inherited Thrombocytopenia
  • Positive family history
+ + + + + + Nl Nl Nl
Thrombotic Thrombocytopenic Purpura (TTP) History of: + + + + + + Nl Nl Nl
Hemolytic Uremic Syndrome History of: + + + + + + Nl Nl Nl
Thromobcytosis Iron deficiency anemia

Inflammatory diseases

Splenectomy

Essential thrombocytosis

± ± Nl or ↑ Nl Nl Nl
Qualitative Disorders of Platelet Function Inherited Disorders of Platelet Function Glanzmann’s thrombasthenia
  • Positive family history
+ + + + Rare Nl or ↓ Nl Nl Nl
  • AR inheritance
  • Absence of the platelet Gp IIb/IIIa receptor
  • Diminished for GP 2B-3A on flow cytometry
Bernard-Soulier syndrome
  • Positive family history
+ + + + Nl or ↓ Nl Nl Nl
  • AR inheritance
  • Absence of the platelet Gp Ib-IX-V receptor
  • On PBS: giant platelets
  • Ristocetin - no aggregation
Wiskott-Aldrich syndrome
  • Positive family history
+ + + + Nl or ↓ Nl Nl Nl
  • Anti-WASP antibody can be used to detect presence or absence of WAS protein
  • In Wiskott–Aldrich syndrome, the platelets are small and do not function properly. They are removed by the spleen, which leads to low platelet counts.
Platelet storage pool disorder (SPD): + + + + Nl or ↓ Nl Nl Nl
  • AD inheritance
  • AbNlities of platelet granule formation
Acquired Disorders of Platelet Function + + + + ± ± Nl or ↓ Nl Nl Nl
Von Willebrand Disease + + + + ± ± Nl Nl See the table below for the details about different types.
Vessel wall disorders Metabolic and Inflammatory Disorders
  • History of the underlying disease.
+ + ± Nl Nl or ↑ Nl Nl Nl
Inherited Disorders of the Vessel Wall
  • Positive family history
+ + ± Nl Nl or ↑ Nl Nl Nl
Coagulation factor disorders

[1]

Fibrinogen deficiency Different types of the fibrinogen disorders: + + ± + Nl
  • Impaired fibrin cross linking or clot dissolution.
  • The severity of bleeding in patients with fibrinogen disorders can be mild or severe, with higher bleeding risk in those with afibrinogenemia or lower levels of functional fibrinogen. The age of onset is also variable, with earlier onset in those with more severe deficiency.
Prothrombin deficiency + + + + + Nl Nl
Factor V deficiency _ + + + + Nl Nl The severity of bleeding is only partly related to the degree of factor V deficiency. Some patients with undetectable plasma levels of factor V experience only relatively mild bleeding.
Factor VII deficiency + + + Nl Nl Nl Thrombosis occurs in inherited factor VII deficiency most cases are associated with the administration of factor VII replacement therapy
Factor X deficiency
  • Prolonged bleeding following circumcision
+ + + + + Nl Nl Nl
Factor XII deficiency
  • Majority,asymptomatic
  • Recurrent miscarriages
  • Painful leg ulcers
_ _ _ _ _ Nl Nl Nl Nl
High molecular weight kininogen (HMWK) deficiency
  • Possibility of positive family history of bleeding
_ _ _ _ _ Nl Nl Nl Nl
Prekallikrein deficiency
  • Possibility of positive family history of bleeding
_ _ _ _ _ Nl Nl Nl Nl
Factor XIII deficiency Types:
  • Sub unit A mutation disease (more common)
  • Sub unit B mutation disease
  • Possibility of positive family history of bleeding
± ± ± ± ± ± Nl Nl Nl or ↑ Nl Nl
  • Impaired fibrin cross linking or clot dissolution
  • The severity of factor XIII deficiency bleeds can be different in different patients
Hemophilia Type A deficiency + + + Nl Nl Nl Nl
Type B deficiency + + + Nl Nl Nl Nl
Type C deficiency
  • Family history
  • Bleeding after surgery or injury
+ Rare Rare Nl Nl Nl Nl
Rare diseases Disseminated Intravascular Coagulation + + + + + + Nl
Vitamin K Deficiency + + + + + Nl Nl or mildly prolonged Nl

Different types of Von-Willebrand diseases can be differentiated from each other based on the following table:

Type of VWD Type of factor deficiency Prevalence Inheritance pattern Clinical manifestations VWF activity RIPA Factor VIII
Type 1 Quantitative/ partial 60-70% AD
  • Bleeding severity mild to severe
Type 2 2A Qualitative 10% AD/AR N or ↓
2B Qualitative 5% AD N or ↓
2M Qualitative <1% AD/AR N or ↓
2N Qualitative <1% AR N N
Type 3 Complete deficiency 1-2% AR Absent Low, 1-10%

For more information on Von Willebrand disease, click here.